Trial Profile

Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered with Membrane Bound IL15 Plus Acetazolamide in Adult Patients with Metastatic Melanoma

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 05 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Acetazolamide (Primary) ; OBX 115 (Primary) ; Cyclophosphamide; Fludarabine; Furosemide; Mesna
Indications Malignant melanoma; Solid tumours
Focus Adverse reactions; First in man

02 Jun 2025 According to Obsidian Therapeutics media release, data this study presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
23 Apr 2025 According to Obsidian Therapeutics media release, data from this trial will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
04 Jun 2024 Results (n=9) presented at the 60th Annual Meeting of the American Society of Clinical Oncology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com